Pharmaceutical

iOnctura expands PI3K inhibitor programme to NSCLC

iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.

Jul 10, 2024 - 04:00
iOnctura expands PI3K inhibitor programme to NSCLC
iOnctura will evaluate roginolisib in combination with GSK’s Jemperli in a Phase II trial.
Read the original article

Tags:

Previous Article

Exponentially increasing understanding of early life on Earth

Next Article

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards

STAT+: Federal regulators, scrambling to keep up with A...

Mar 4, 2024

The Genomic Medicine Revolution: Multi-Modality Approaches in Advanced Therapies 

The Genomic Medicine Revolution: Multi-Modality Approac...

Aug 17, 2024

Pfizer gets grant for treatment of cancer using enginee...

Apr 25, 2024